Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
8 studies found for:    21870978 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
Conditions: Atrial Fibrillation;   End Stage Renal Disease
Interventions: Drug: apixaban;   Drug: warfarin
2 Recruiting Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
Conditions: Coronary Artery Bypass Grafting;   Postoperative Atrial Fibrilation;   Stroke;   Systemic Embolism;   Deep Venous Thrombosis
Interventions: Drug: Apixaban;   Drug: Warfarin
3 Recruiting Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
Condition: Atrial Fibrillation
Interventions: Drug: Dabigatran etexilate;   Drug: Rivaroxaban;   Drug: Apixaban
4 Recruiting Direct Oral Anticoagulants Pharmacodynamics in Octogenarian Patients With Atrial Fibrillation
Condition: Atrial Fibrillation and Flutter
Intervention: Other: New oral anticoagulant pharmacodynamic analysis (blood level assesment)
5 Recruiting Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation
Condition: Atrial Fibrillation
Interventions: Drug: NOAC;   Device: Left atrial appendage closure
6 Recruiting Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiphosPholipid Syndrome
Conditions: Antiphospholipid Syndrome;   Thrombosis
Interventions: Drug: Apixaban;   Drug: Warfarin
7 Completed
Has Results
Genetic Response to Warfarin in Healthy Subjects
Condition: Healthy
Intervention: Drug: Warfarin
8 Completed
Has Results
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
Conditions: Atrial Fibrillation;   Atrial Flutter
Interventions: Drug: warfarin;   Drug: apixaban

Indicates status has not been verified in more than two years